CHEMM Stock Overview
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ChemoMetec A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 448.00 |
| 52 Week High | DKK 554.00 |
| 52 Week Low | DKK 281.20 |
| Beta | 1.26 |
| 11 Month Change | 7.02% |
| 3 Month Change | 18.90% |
| 1 Year Change | 23.62% |
| 33 Year Change | -49.32% |
| 5 Year Change | 73.64% |
| Change since IPO | 1,936.36% |
Recent News & Updates
Recent updates
ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Nov 09
We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings
Sep 18What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You
Jul 29Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%
Jul 29What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?
Jul 03Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%
Apr 15What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You
Mar 01What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?
Mar 01Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 08Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares
Dec 21Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?
Nov 15ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 17A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)
Sep 15At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?
Jun 20With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case
Jun 01Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors
Jan 24If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity
Oct 26Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?
Oct 05Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?
Jul 18Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock
Mar 27Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?
Dec 12Shareholder Returns
| CHEMM | DK Life Sciences | DK Market | |
|---|---|---|---|
| 7D | -4.2% | -6.0% | -1.0% |
| 1Y | 23.6% | 1.4% | 7.5% |
Return vs Industry: CHEMM exceeded the Danish Life Sciences industry which returned 1.6% over the past year.
Return vs Market: CHEMM exceeded the Danish Market which returned 6.2% over the past year.
Price Volatility
| CHEMM volatility | |
|---|---|
| CHEMM Average Weekly Movement | 10.5% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 10.5% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: CHEMM's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: CHEMM's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 174 | Martin Behrens | chemometec.com |
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer.
ChemoMetec A/S Fundamentals Summary
| CHEMM fundamental statistics | |
|---|---|
| Market cap | DKK 7.80b |
| Earnings (TTM) | DKK 136.28m |
| Revenue (TTM) | DKK 407.87m |
57.2x
P/E Ratio19.1x
P/S RatioIs CHEMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHEMM income statement (TTM) | |
|---|---|
| Revenue | DKK 407.87m |
| Cost of Revenue | DKK 40.28m |
| Gross Profit | DKK 367.60m |
| Other Expenses | DKK 231.31m |
| Earnings | DKK 136.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 7.83 |
| Gross Margin | 90.13% |
| Net Profit Margin | 33.41% |
| Debt/Equity Ratio | 0.2% |
How did CHEMM perform over the long term?
See historical performance and comparison